MKMorvarid Karimi

Morvarid Karimi

*This is an algorithmically generated author record based on publicly available information.

Morvarid Karimi has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Radiation dosimetry of [18F]VAT in nonhuman primates

    by Morvarid Karimi, Zhude Tu, Xuyi Yue, Xiang Zhang, Hongjun Jin, Joel S. Perlmutter, Richard Laforest

    The objective of this study is to determine the radiation dosimetry of a novel radiotracer for vesicular acetylcholine transporter (−)-(1-((2R,3R)-8-(2-[18F]fluoro-ethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)piperidin-4-yl)(4-fluorophenyl)-methanone ([18F]VAT) based on PET imaging in nonhuman primates. [18F]VAT has potential for investigation of neurological disorders including Alzheimer’s disease, Parkinson’s disease, and dystonia. Three macaque fascicularis (two males, one female) received 185.4–198.3 MBq [18F]VAT prior to whole-body imaging in a MicroPET-F220 scanner. Time activity curves (TACs) were created from regions of interest (ROIs) that encompassed the entire small organs or samples with the highest activity within large organs. Organ residence times were calculated based on the TACs. We then used OLINDA/EXM 1.1 to calculate human radiation dose estimates based on scaled organ residence times. Measurements from directly sampled arterial blood yielded a residence time of 0.30 h in agreement with the residence time of 0.39 h calculated from a PET-generated time activity curve measured in the left ventricle. Organ dosimetry revealed the liver as the critical organ (51.1 and 65.4 μGy/MBq) and an effective dose of 16 and 19 μSv/MBq for male and female, respectively. The macaque biodistribution data showed high retention of [18F]VAT in the liver consistent with hepatobiliary clearance. These dosimetry data support that relatively safe doses of [18F]VAT can be administered to obtain imaging in humans.


  • Striatal dopamine D1-like receptor binding is unchanged in primary focal dystonia

    by Morvarid Karimi, Stephen M. Moerlein, Tom O. Videen, Yi Su, Hubert P. Flores Ms, Joel S. Perlmutter


  • Decreased striatal dopamine receptor binding in primary focal dystonia: A D2 or D3 defect?

    by Morvarid Karimi, Stephen M. Moerlein, Tom O. Videen, Robert R. Luedtke, Michelle Taylor, Robert H. Mach, Joel S. Perlmutter

    Dystonia is an involuntary movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures. Several lines of evidence suggest that abnormalities of dopaminergic pathways contribute to the pathophysiology of dystonia. In particular, dysfunction of D2‐like receptors that mediate function of the indirect pathway in the basal ganglia may play a key role. We have demonstrated with positron emission tomography that patients with primary focal cranial or hand dystonia have reduced putamenal specific binding of [18F]spiperone, a nonselective D2‐like radioligand with nearly equal affinity for serotonergic 5‐HT(2A) sites. We then repeated the study with [18F]N‐methyl‐benperidol (NMB), a more selective D2‐like receptor radioligand with minimal affinity for 5‐HT(2A). Surprisingly, there was no decrease in NMB binding in the putamen of subjects with dystonia. Our findings excluded reductions of putamenal uptake greater than 20% with 95% confidence intervals. The analysis of the in vitro selectivity of NMB and spiperone demonstrated that NMB was highly selective for D2 receptors relative to D3 receptors (200‐fold difference in affinity), whereas spiperone has similar affinity for all three of the D2‐like receptor subtypes. These findings when coupled with other literature suggest that a defect in D3, rather than D2, receptor expression may be associated with primary focal dystonia. © 2010 Movement Disorder Society.


    • 1 April 2010
      • Vol. 127  (4) , 470

    Novel human pathological mutations. Gene symbol: THAP1. Disease: dystonia 6.

    by Jianfeng Xiao, Robert W Bastian, Joel S Perlmutter, Brad A Racette, Samer D Tabbal, Morvarid Karimi, Randal Paniello, Andrew Blitzer, Sat Dev Batish, Zbigniew K Wszolek, et al.

  • Open Access

    High-throughput mutational analysis of TOR1A in primary dystonia

    by Jianfeng Xiao, Robert W Bastian, Joel S Perlmutter, Brad A Racette, Samer D Tabbal, Morvarid Karimi, Randal C Paniello, Andrew Blitzer, Sat Dev Batish, Zbigniew K Wszolek, et al.

    Although the c.904_906delGAG mutation in Exon 5 of TOR1A typically manifests as early-onset generalized dystonia, DYT1 dystonia is genetically and clinically heterogeneous. Recently, another Exon 5 mutation (c.863G>A) has been associated with early-onset generalized dystonia and some ΔGAG mutation carriers present with late-onset focal dystonia. The aim of this study was to identify TOR1A Exon 5 mutations in a large cohort of subjects with mainly non-generalized primary dystonia.


  • Open Access

    (undefined)

    by Morvarid Karimi, Joel S. Perlmutter